Zymeworks Announces Participation in Upcoming Investor Conferences
August 01 2022 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing next-generation multifunctional biotherapeutics,
today announced that management will participate in an upcoming
investor conference:
- Citi’s 17th Annual BioPharma Conference. Zymeworks will
participate in one-on-one meetings and management will participate
in a fireside chat on September 7th in Boston, MA.
- 2022 Wells Fargo Healthcare Conference. Zymeworks will
participate in one-on-one meetings and management will participate
in a fireside chat on September 8th in Boston, MA.
- Morgan Stanley 20th Annual Global Healthcare Conference.
Zymeworks will participate in one-on-one meetings on September 13th
and 14th in New York, NY.
- H.C. Wainwright 24th Annual Global Investment
Conference. Zymeworks will virtually participate in one-on-one
meetings on September 13th and 14th and will make available a
pre-recorded presentation on September 12th.
The presentation and fireside chats will be available on
Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc. Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the discovery, development
and commercialization of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab, is a novel Azymetric™
HER2-targeted bispecific antibody currently being evaluated in
multiple Phase 1, Phase 2, and pivotal clinical trials globally as
a targeted treatment option for patients with solid tumors that
express HER2. Zymeworks’ second clinical candidate, zanidatamab
zovodotin (ZW49), is a novel bispecific HER2 ‑targeted
antibody-drug conjugate currently in Phase 1 clinical development
and combines the unique design and antibody framework of
zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and
cytotoxin. Zymeworks is also advancing a deep preclinical pipeline
in oncology (including immuno-oncology agents) and other
therapeutic areas. In addition, its therapeutic platforms are being
leveraged through strategic partnerships with global
biopharmaceutical companies. For more information on our ongoing
clinical trials visit www.zymeworksclinicaltrials.com. For
additional information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220801005087/en/
Investor Inquiries: Jack Spinks (604) 678-1388
ir@zymeworks.com
Media Inquiries: Diana Papove (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024